Valuation: Organon & Co.

Market Cap 3.63B 3.26B 2.99B 2.71B 5.07B 345B 5.17B 35.71B 14.33B 182B 13.64B 13.35B 572B P/E 2026 *
6.18x
P/E 2027 * 5.2x
Enterprise Value 10.69B 9.57B 8.8B 7.98B 14.91B 1,015B 15.19B 105B 42.15B 534B 40.11B 39.26B 1,683B EV / Sales 2026 *
1.74x
EV / Sales 2027 * 1.56x
Free-Float
99.54%
Yield 2026 *
0.58%
Yield 2027 * 0.58%
1 day+0.22%
1 week+0.65%
Current month+1.02%
1 month+1.02%
3 months+2.14%
6 months+4.45%
Current year+93.03%
1 week 13.74
Extreme 13.74
13.84
1 month 13.7
Extreme 13.7
13.84
Current year 5.69
Extreme 5.69
13.84
1 year 5.69
Extreme 5.69
13.84
3 years 5.69
Extreme 5.69
23.1
5 years 5.69
Extreme 5.69
39.48
10 years 5.69
Extreme 5.69
39.48
Manager TitleAgeSince
Chief Executive Officer 61 2025-10-25
Director of Finance/CFO 59 2021-06-01
Compliance Officer - -
Director TitleAgeSince
Chairman 68 2021-06-01
Director/Board Member 78 2021-06-01
Director/Board Member 72 2021-06-01
Date Insider Type Main position Quantity % Market Cap. Importance
8/11/26 Exercice

Chief Technology Officer

27,172 0.0103%
8/5/26 Sell

Head of Mfg & Supply

-14,761 0.0056%
6/12/26 Free

Director

17,857 0.0068%
Change 5-day change 1-year change 3-year change Capi.($)
+0.22%+0.65%+110.65%-7.30% 3.63B
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +1.58%+5.37%+53.00%+74.09% 426.56B
Weighted average by Cap. +1.19%+6.59%+50.93%+98.22%

Financials

2026 *2027 *
Net sales 6.16B 5.51B 5.07B 4.6B 8.59B 585B 8.75B 60.49B 24.28B 308B 23.11B 22.62B 970B 6.29B 5.63B 5.18B 4.69B 8.77B 597B 8.93B 61.75B 24.79B 314B 23.59B 23.09B 990B
Net income 601M 538M 495M 449M 839M 57.07B 854M 5.9B 2.37B 30.02B 2.26B 2.21B 94.67B 721M 646M 594M 538M 1.01B 68.46B 1.02B 7.08B 2.84B 36.01B 2.71B 2.65B 114B
Net Debt 7.05B 6.32B 5.81B 5.26B 9.84B 670B 10.03B 69.29B 27.81B 352B 26.47B 25.91B 1,111B 6.17B 5.53B 5.09B 4.61B 8.62B 586B 8.78B 60.66B 24.35B 308B 23.17B 22.68B 973B
Projected Income Statement - Annual - Organon & Co.
Logo Organon & Co.
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Employees
10,000
Date Price Change Volume
26-10-30 US$13.84 +0.22% 1,848,063
26-10-29 US$13.81 +0.22% 2,510,119
26-10-28 US$13.78 +0.22% 3,162,986
26-10-27 US$13.75 +0.07% 1,865,054
26-10-26 US$13.74 -0.07% 1,548,458
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Organon & Co.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
13.84USD
Average target price
10.33USD
Spread / Average Target
-25.34%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Organon & Co.